Trevi Therapeutics Prices $150M Public Offering
Analysis based on 15 articles · First reported Apr 16, 2026 · Last updated Apr 17, 2026
The market is positively impacted by Trevi Therapeutics' successful public offering, as it provides capital for the company's drug development, potentially leading to future growth. The involvement of several investment banks also indicates market confidence in the offering.
Trevi Therapeutics, a clinical-stage biopharmaceutical company, announced the pricing of its underwritten public offering of 11,600,000 shares of common stock at $13.00 per share, aiming to raise approximately $150 million. The company also granted underwriters a 30-day option to purchase an additional 1,740,000 shares. The offering is expected to close around April 20, 2026. Morgan Stanley, Leerink Partners, Cantor, and Stifel are serving as joint book-running managers, with Oppenheimer & Co. as lead manager. The proceeds will support the development of Haduvio, an investigational therapy for chronic cough.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard